Spesolimab

BLUE BELL, Pa.--(BUSINESS WIRE)--Ladder Bio, Inc., a structure-guided biotechnology company developing Spiroligomers™, a new class of chemical matter as medicines, today announced the appointments of Jay Fine, PhD, and John Prufeta to its Board of Directors. The two appointments add deep drug development experience and defense-sector expertise as Ladder Bio advances its proprietary Spiroligomer™ platform across immunology, oncology, and biosecurity applications. Spiroligomers (pronounced: SPEER-oh-LIG-oh-mers) are synthetic, modular, fused-ring structures with a diverse range of functional groups, allowing exquisite control of their molecular shapes and sizes. Dr. Fine currently serves as President, Research & Development at EvolveImmune Therapeutics. He possesses over 30 years of strategic leadership in drug discovery and development, covering immunology, immune-oncology, inflammatory diseases, and respiratory disorders. Prior to joining EvolveImmune, Dr. Fine served as Senior Vice President and Global Therapeutic Area Head, and as US Research Site Head, at Boehringer Ingelheim. His teams played a seminal role in the discovery and development of Skyrizi™, Spevigo™ and Jascayd™ and delivered over 30 molecules into clinical development. Previously, Jay held leadership positions at Roche and Schering-Plough and at the National Cancer Institute. His expertise in drug discovery and development will undoubtedly be valuable in whichever areas the Company will pursue now and in the future. Mr. Prufeta is the Founder & General Partner of Medical Excellence Capital (MEC), the biotechnology venture capital firm that led Ladder Bio’s Series Seed financing. MEC invests at the convergence of biotechnology, computation, and national security, with a focus on breakthrough platforms capable of advancing both human health and U.S. bioeconomic resilience. Mr. Prufeta also serves on the Board of Directors of Business Executives for National Security (BENS), the nonpartisan organization through which senior business and national security leaders apply private-sector expertise to critical U.S. defense and homeland security priorities. To date, Ladder Bio has secured more than $16.9 million in non-dilutive funding from the U.S. Department of Defense and the Defense Threat Reduction Agency (DTRA), supporting the continued development of the company’s platform for biodefense, pandemic preparedness, and broader biosecurity applications. "We are grateful to welcome Jay and John to the Ladder Bio Board," said Eric Heil, Chairman and CEO of Ladder Bio. "Few drug developers can point to a multi-billion-dollar medicine they helped bring to patients, and few investors can point to deeper relationships across the defense, biotechnology, and biosecurity ecosystem. Jay's experience taking novel therapies from discovery through approval is directly relevant to the development path Ladder Bio is pursuing across our pipeline of novel Spiroligomer therapeutics for validated immunology targets. John's leadership through MEC and BENS continues to deepen the platform's access to the non-dilutive defense funding that has been foundational to Ladder Bio's progress to date." "Ladder Bio is taking an exciting, highly unique approach by pairing a rationally designed, structurally privileged molecule class with an AI-guided, structure-based design engine that closes the loop between target structure and synthesizable medicines," said Dr. Fine. "There are substantial opportunities to apply this differentiated platform to validated immunology targets and beyond. I am pleased to join the Board and to help the team translate this pioneering science into medicines for patients." “Ladder Bio represents the type of platform innovation that can simultaneously reshape therapeutic development and strengthen national biosecurity preparedness,” said Mr. Prufeta. “The company’s combination of novel chemistry, AI-enabled drug design, and dual-use potential creates a uniquely compelling strategic opportunity. I am pleased to formalize my role on the Board and to continue working alongside my MEC partner Eric and the team as the platform advances and as its relationships across the biotechnology, defense, and biosecurity ecosystem continue to expand.” These appointments reflect Ladder Bio's continued momentum as it advances its Spiroligomer platform and CanDo AI design engine toward in vivo proof-of-concept of its lead program, establishment of key partnerships with additional immunology and oncology programs, and an active DTRA program supporting the platform's biosecurity capabilities. About Ladder Bio Ladder Bio (formerly ThirdLaw Molecular) is a therapeutics company developing Spiroligomer™ ladder-shaped peptide-like molecules—sequence-defined, structurally preorganized molecules designed to be orally available, cell permeable, and engage challenging biological targets with high affinity and selectivity. Ladder Bio’s platform integrates rational design with modern discovery to create new treatment options for patients where conventional modalities fall short. Ladder Bio is headquartered in Blue Bell, PA, a suburb of Philadelphia. Learn more: ladderbio.com *Forward-looking statements: This release contains forward-looking statements regarding Ladder Bio's pipeline, platform, and development plans. Actual results may differ materially. Ladder Bio undertakes no obligation to update any forward-looking statement.*

BALLERUP, Denmark--(BUSINESS WIRE)--In Q1 2026, LEO Pharma delivered robust revenue growth, driven by the dermatology portfolio, and improved profitability while significantly increasing commercial investments to support the global roll-out of Anzupgo ® and the addition of Spevigo ® to the portfolio. LEO Pharma also made significant strategic progress and advanced innovation through the acquisition of Replay’s next-generation gene therapy platform targeting rare genetic skin diseases, the approval of Enstilar ® in China and the continued late-stage development activities for Anzupgo ® , including FDA acceptance for review in adolescents with chronic hand eczema. Financial highlights LEO Pharma’s revenue increased by 4% to DKK 3,521 million, and by 9% at constant exchange rates (CER). The revenue growth was led by North America (30% at CER) and Rest of World (13% at CER), whereas sales in Europe declined by 1% at CER. Revenue from the dermatology portfolio grew by 11% (CER), driven by the strategic brands Anzupgo ® , Spevigo ® and Adtralza ® /Adbry ® , which combined had a revenue increase of 43% (CER), in addition to growth of 1% (CER) in the established brands. Sales in the Critical Care portfolio grew by 3% (CER). Operating profit improved, with adjusted EBITDA increasing by 12% to DKK 610 million in Q1 2026. The adjusted EBITDA margin improved to 17% (Q1 2025: 16%) led by gross margin expansion to 65% (Q1 2025: 58%), offsetting higher commercial investments. Net profit for Q1 2026 was DKK 99 million (Q1 2025: DKK 1,742 million), including non-recurring items. Excluding non-recurring items, net profit improved by DKK 132 million to DKK 142 million in Q1 2026. Free cash flow was DKK 336 million for Q1 2026 (Q1 2025: DKK 1,386 million), and net interest-bearing debt was reduced to DKK 8,987 million (YE 2025: DKK 9,358 million). Excluding M&A, free cash flow improved by DKK 581 million compared to Q1 2025. Innovation highlights Acquisition of Replay, announced on 30 April 2026, adding a next-generation gene therapy platform for topical delivery in rare genetic skin diseases and further expanding LEO Pharma’s presence in rare dermatology. FDA accepted for review the label expansion sNDA for Anzupgo ® (delgocitinib) cream for adolescents aged 12 to 17 years with moderate to severe chronic hand eczema in the U.S. China’s NMPA approved Enstilar ® (calcipotriene/betamethasone dipropionate) foam for the treatment of plaque psoriasis in adults, expanding access to a new treatment option for more than an estimated 6 million adults in the country. 2026 outlook 2026 revenue growth of 8-11% (CER) is unchanged, while the adjusted EBITDA margin outlook is revised to 15-18% (previously: 16-19%) reflecting increased spending on development activities following the acquisition of Replay. "We are off to a robust start to 2026, with improved profitability and strong cash flow, while continuing to invest in our commercial capabilities to support future growth. With our agreement to acquire Replay, we are adding a next-generation gene therapy technology that further expands LEO Pharma’s presence in rare dermatology and supports our focus on advancing innovation and leveraging our global platform to address significant unmet patient needs.” CEO Christophe Bourdon About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. Headquartered in Denmark, LEO Pharma has a team of 4,300 people worldwide. Together, we reach far beyond the skin. For more information, visit Contacts For further information please contact: I nvestor Relations: Christian Boas Ryom, telephone +45 4494 5888 Media: Jeppe Ilkjær, telephone +45 3050 2014